Niraparib Tosylate APIs are a part of Loncom Pharma’s oncology line-up, serving as maintenance treatment for ovarian cancer. As a PARP inhibitor, it plays a crucial role in exploiting cancer cell DNA repair pathway deficiencies, thus preventing cancer progression.
